NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ZEALAND PHARMA/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $32.87 +1.81 (+5.83 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$30.98Now: $32.87▼$32.8750-Day Range$26.46MA: $30.36▼$36.6052-Week Range$11.56Now: $32.87▼$36.84Volume4,181 shsAverage Volume9,928 shsMarket Capitalization$1.05 billionP/E Ratio10.96Dividend YieldN/ABeta2.06 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZEAL Previous Symbol CUSIPN/A CIK1674988 Webhttp://www.zealandpharma.com/ Phone45-8877-3600Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio5.18Price-To-Earnings Trailing P/E Ratio10.96 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.02 million Price / Sales173.74 Cash Flow$3.21 per share Price / Cash Flow10.25 Book Value$5.49 per share Price / Book5.99Profitability EPS (Most Recent Fiscal Year)$3.00 Net Income$92.07 million Net MarginsN/A Return on Equity-43.92% Return on Assets-36.02%Miscellaneous Employees149 Outstanding Shares31,820,000Market Cap$1.05 billion Next Earnings Date3/5/2020 (Estimated) OptionableNot Optionable Receive ZEAL News and Ratings via Email Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ZEAL Rates by TradingView ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions What is ZEALAND PHARMA/S's stock symbol? ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL." How were ZEALAND PHARMA/S's earnings last quarter? ZEALAND PHARMA/S (NASDAQ:ZEAL) posted its quarterly earnings data on Thursday, November, 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.18. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $7.50 million. View ZEALAND PHARMA/S's Earnings History. When is ZEALAND PHARMA/S's next earnings date? ZEALAND PHARMA/S is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for ZEALAND PHARMA/S. What price target have analysts set for ZEAL? 5 brokerages have issued 12-month price objectives for ZEALAND PHARMA/S's stock. Their forecasts range from $30.00 to $42.00. On average, they anticipate ZEALAND PHARMA/S's share price to reach $37.67 in the next year. This suggests a possible upside of 14.6% from the stock's current price. View Analyst Price Targets for ZEALAND PHARMA/S. What is the consensus analysts' recommendation for ZEALAND PHARMA/S? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZEALAND PHARMA/S. Has ZEALAND PHARMA/S been receiving favorable news coverage? News stories about ZEAL stock have been trending extremely positive this week, according to InfoTrie. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a news impact score of 4.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for ZEALAND PHARMA/S. Who are some of ZEALAND PHARMA/S's key competitors? Some companies that are related to ZEALAND PHARMA/S include FibroGen (FGEN), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Blueprint Medicines (BPMC), Taro Pharmaceutical Industries (TARO), Nektar Therapeutics (NKTR), Intercept Pharmaceuticals (ICPT), SAGE Therapeutics (SAGE), Evotec (EVTCY), Alkermes (ALKS), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Myokardia (MYOK) and Genmab A/S (GMAB). What other stocks do shareholders of ZEALAND PHARMA/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), Tandem Diabetes Care (TNDM), Ford Motor (F), Wells Fargo & Co (WFC), NVIDIA (NVDA), Alibaba Group (BABA) and Radius Health (RDUS). Who are ZEALAND PHARMA/S's key executives? ZEALAND PHARMA/S's management team includes the folowing people: Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 66)Dr. Emmanuel Dulac Ph.D., PharmD, MBA, CEO & Pres (Age 49)Mr. Ivan Mourits Møller, Interim CFO and Sr. VP of Technical Devel. & Operations (Age 47)Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 54)Lani Pollworth Morvan, Investor Relations & Communications Officer When did ZEALAND PHARMA/S IPO? (ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. How do I buy shares of ZEALAND PHARMA/S? Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ZEALAND PHARMA/S's stock price today? One share of ZEAL stock can currently be purchased for approximately $32.87. How big of a company is ZEALAND PHARMA/S? ZEALAND PHARMA/S has a market capitalization of $1.05 billion and generates $6.02 million in revenue each year. The company earns $92.07 million in net income (profit) each year or $3.00 on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe.View Additional Information About ZEALAND PHARMA/S. What is ZEALAND PHARMA/S's official website? The official website for ZEALAND PHARMA/S is http://www.zealandpharma.com/. How can I contact ZEALAND PHARMA/S? ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected] MarketBeat Community Rating for ZEALAND PHARMA/S (NASDAQ ZEAL)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 230 (Vote Outperform)Underperform Votes: 243 (Vote Underperform)Total Votes: 473MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/7/2019 by MarketBeat.com StaffFeatured Article: Understanding Compound Annual Growth Rate (CAGR)
